Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.8K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.8K
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

5.9K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.9K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

3.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Ste20 kinase TAOK3 restrains Rac-driven cytoskeletal-mitochondrial coupling to preserve naive CD8<sup>+</sup> T cell homeostasis and activation.

Frontiers in immunology·2026
Same author

Desensitization With Tocilizumab and IVIg: A Prospective Controlled Cohort Study in a Predominantly Black American Population.

Transplantation·2026
Same author

Complementary Roles of Tissue-based Gene Expression and Donor-derived Cell-free DNA for Therapy of Mild and Moderate T-cell-mediated Rejection in Kidney Transplants.

Transplantation·2026
Same author

Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Assessing the capability of large language models in answering pediatric critical care board-style questions.

Scientific reports·2026
Same author

<i>Trans</i>-eQTLs reveal the architecture of human gene regulatory networks.

medRxiv : the preprint server for health sciences·2026

相关实验视频

Updated: May 3, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.5K

造价刺激封锁:下一代的新一代

Idris Yakubu1, Irfan Moinuddin2, Andrew Brown1

  • 1Department of Pharmacy, Virginia Commonwealth University Health System.

Current opinion in organ transplantation
|January 30, 2025
PubMed
概括
此摘要是机器生成的。

针对移植患者的新型免疫抑制疗法旨在改善长期结果和简化管理. 调查代理提供有针对性的方法,可能改善移植存活率和患者护理.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.7K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

793

相关实验视频

Last Updated: May 3, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.7K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

793

科学领域:

  • 免疫学 免疫学 免疫学
  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 移植医学 移植医学

背景情况:

  • 氨酸抑制剂 (CNIs) 是用于移植免疫抑制的标准,但会导致长期并发症.
  • 贝拉塔塞普特 (Belatacept) 提供了一个替代方案,但在高风险患者的治疗和疗效方面存在局限性.

研究的目的:

  • 审查用于移植的新兴免疫抑制疗法.
  • 突出成本刺激封锁方面的进展及其对长期结果和可访问性的潜在影响.

主要方法:

  • 对移植中新型免疫抑制剂的当前文献的综述.
  • 对针对CTLA-4,CD28,CD40/CD40L通路的药物进行临床试验数据的分析.

主要成果:

  • 阿巴cept显示出有希望的结果;VEL-101和卢利祖马布可以选择性地阻断CD28.
  • CD40/CD40L通路的药物具有混合的结果,但针对CD40L的药物在预防中显示出有效性.
  • 目前正在开发可通过皮下输送的研究药物.

结论:

  • 该领域正在向更安全,更容易获得的长期免疫抑制策略迈进.
  • 皮下输送方法可以改善患者的坚持和患者管理.
  • 在辅助刺激阻塞方面的进步可能会改善移植的存活率,并改变移植护理.